High materiality9/10
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts
Why it may matterVerify against the original reporting
Downgrades and reduced price target indicate a significant negative outlook.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
BofA downgraded Editas citing limited near-term catalysts. Editas is partnering for reni-cel in sickle cell disease. Analyst estimates of success in SCD and beta-thal dropped to 10%. Competitors are advancing their SCD and thalassemia programs aggressively. EDIT's price target was reduced to $1 from $13.
- BofA downgraded Editas citing limited near-term catalysts.
- Editas is partnering for reni-cel in sickle cell disease.
- Analyst estimates of success in SCD and beta-thal dropped to 10%.
- Competitors are advancing their SCD and thalassemia programs aggressively.
- EDIT's price target was reduced to $1 from $13.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.